Skip to content
NewsBlazeAU – Lifestyle
Author:
Arcutis Biotherapeutics, Inc.
Arcutis Begins Enrolling Phase 3 Study Evaluating ZORYVE® (roflumilast) Cream 0.3% in Moderate to Severe Atopic Dermatitis
November 5, 2026
Arcutis Announces Third Quarter 2026 Financial Results and Provides Business Update
November 4, 2026
Arcutis Appoints Rob Scott, MD to Board of Directors
October 28, 2026
Arcutis Management to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
October 27, 2026
Arcutis to Report Third Quarter 2026 Financial Results and Host Conference Call on November 4, 2026
October 21, 2026
Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical
October 13, 2026
Arcutis’ ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award
October 6, 2026
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 2, 2026
Simone Biles Partners with Arcutis to Launch the Skin to Believe In Campaign, Raising Awareness of Seborrheic Dermatitis and Eczema, and Inspiring People to Explore Treatment Options
September 29, 2026
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 4, 2026
1
2
3
Next Page
→